ReviewJournal of B.U.ON. : official journal of the Balkan Union of Oncology2009
Novel modular transporters delivering anticancer drugs and foreign DNA to the nuclei of target cancer cells.
Review in Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Biophysical Characterization and Anticancer Activities of Photosensitive Phytoanthraquinones Represented by Hypericin and Its Model Compounds.Molecules (Basel, Switzerland) · 2020Review
- Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.Current pharmaceutical design · 2015Review
- Nuclear localization signals in phage terminal proteins provide a novel gene delivery tool in mammalian cells.Communicative & integrative biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
A major challenge in the development of specific and effective cancer treatments is the paradoxical situation that exploiting a molecular target that is accessible (surface membrane or extracellular matrix) is critical for achieving tumor selectivity whereas delivery of the therapeutic inside the cell, to the cell nucleus is generally required for maximizing the therapeutic effect. Photosensitizers, alpha-particle emitting radionuclides and foreign genetic material could be considered as such therapeutics if they possessed cellular and subcellular specificity. The author describes a novel approach of using modular recombinant transporters to target the therapeutics to the nucleus of cancer cells, where their action is most pronounced or can only be expressed. Photo-sensitizer-transporter conjugates displayed up to 3000 times greater efficacy than free photosensitizers and acquired cell specificity in contrast to free photosensitizers. Alpha-emitting radionuclides, conjugated with the modular transporters, acquired similar properties. DNA complexed with analogous transporters efficiently transfected target cells. The different modules of the transporters are interchangeable, meaning that they can be tailored for particular applications.
Indexed as
Identifiers
19785068PMC2834187W2142522522What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.